Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review) 2025-05-23 11:39
Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression 2025-05-07 07:30
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong 2025-04-30 07:45
Everest Medicines Announces the "B" Marker Removal from Company's Stock Code, Effective May 2, 2025 2025-04-28 07:30
Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange 2025-04-22 07:45
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024 2025-03-26 11:03
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14 2025-03-24 07:30
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine 2025-03-06 16:30
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs 2025-02-28 14:28
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025 2025-02-26 07:45
Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025 2025-02-25 18:28
Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients 2024-12-18 08:00
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis 2024-12-17 11:48
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients 2024-12-12 11:48
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy 2024-12-04 09:10
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong 2024-12-02 07:40
Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List 2024-11-28 13:43
Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy 2024-11-27 19:08
Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity 2024-11-22 12:14
Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea's Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy 2024-11-19 07:40
1 2 3 4 5 9